Amalgamated Bank Purchases 16,085 Shares of Pfizer Inc. (NYSE:PFE)

Amalgamated Bank lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 1.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,101,526 shares of the biopharmaceutical company's stock after acquiring an additional 16,085 shares during the quarter. Amalgamated Bank's holdings in Pfizer were worth $27,913,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Bessemer Group Inc. raised its holdings in shares of Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after acquiring an additional 13,228 shares in the last quarter. Sage Mountain Advisors LLC raised its holdings in shares of Pfizer by 7.3% in the fourth quarter. Sage Mountain Advisors LLC now owns 20,587 shares of the biopharmaceutical company's stock valued at $546,000 after acquiring an additional 1,404 shares in the last quarter. Penobscot Investment Management Company Inc. raised its holdings in shares of Pfizer by 2.7% in the first quarter. Penobscot Investment Management Company Inc. now owns 95,301 shares of the biopharmaceutical company's stock valued at $2,415,000 after acquiring an additional 2,527 shares in the last quarter. Brighton Jones LLC raised its holdings in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Finally, Acorn Financial Advisory Services Inc. ADV raised its holdings in shares of Pfizer by 32.8% in the fourth quarter. Acorn Financial Advisory Services Inc. ADV now owns 9,288 shares of the biopharmaceutical company's stock valued at $246,000 after acquiring an additional 2,292 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on PFE shares. Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price for the company. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Trading Down 0.2%

Shares of Pfizer stock opened at $24.20 on Monday. The firm's 50 day simple moving average is $23.46 and its two-hundred day simple moving average is $24.84. The firm has a market capitalization of $137.56 billion, a price-to-earnings ratio of 17.53, a PEG ratio of 0.88 and a beta of 0.57. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business's revenue for the quarter was down 7.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.82 EPS. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.11%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.